IL-2 augments the therapeutic efficacy of adoptively transferred B cells which directly kill tumor cells via the CXCR4/CXCL12 and perforin pathways

Author:

Xia Yang12,Tao Huimin134,Hu Yangyang13,Chen Quanning15,Chen Xin16,Xia Leiming12,Zhou Li17,Wang Yi2,Bao Yangyi2,Huang Shiang3,Ren Xiubao7,Lundy Steven K.8,Dai Fu2,Li Qiao1,Chang Alfred E.1

Affiliation:

1. Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA

2. The No.1 People's Hospital of Hefei, Hefei, China

3. Hubei Province Stem Cell Research & Appling Center, Wuhan Union Hospital, Wuhan, China

4. Current address: Fuda Cancer Hospital, Jinan University School of Medicine and Fuda Cancer Institute, Guangzhou, China

5. Department of General Surgery, Tongji Hospital of Tongji University, Shanghai, China

6. Department of Oncology, Wuhan University, Renmin Hospital, Wuhan, China

7. Department of Biotherapy, Tianjin University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key laboratory of Cancer Immunology and Biotherapy, Tianjin, China

8. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3